Today on International Women’s Day, we celebrate the pioneering and trailblazing women at the forefront of drug discovery at HotSpot, as well as across the healthcare industry, whose innovation is essential to the advancement of science and medicine. #IWD2024 #InspireInclusion

Check out the latest blog from HotSpot CEO Jonathan Montagu that highlights promising science emerging from the immuno-oncology field in recent months.

The HotSpot team gathered in Boston for a stimulating week of conversation and collaboration, the highlight of which was a team-wide painting activity of the city’s skyline. The creativity really shines through!

At today’s AACR Advances in Malignant Lymphoma Conference, we’re presenting preclinical data on HST-1021, our MALT1 scaffolding inhibitor. Swing by the poster today at 5:30 PM ET if you’re in Philadelphia! hotspotthera.com/press_release/…

Join us in Barcelona at this year’s ESMO Congress 2024 for a Proffered Paper oral presentation featuring initial data from our first-in-human Phase 1 clinical trial of HST-1011, our novel, selective CBL-B inhibitor. We hope to see you there! hotspotthera.com/press_release/…

We’re looking forward to our presentation tomorrow at ESMO, where we’ll be presenting Phase 1 clinical data for HST-1011, our novel CBL-B inhibitor. Check out our latest release to learn more! hotspotthera.com/press_release/…

Thanks to all who joined today’s presentation at ESMO! We appreciated the chance to share our data with the scientific community, and we’re looking forward to engaging in stimulating discussions and learning of important scientific advancements throughout the rest of the weekend.

We’re thrilled to welcome Alison O’Neill, M.D., who is joining HotSpot as Chief Medical Officer. Dr. O’Neill brings extensive clinical development experience, and she will be pivotal in advancing our pipeline of allosteric inhibitors. Learn more here: hotspotthera.com/press_release/…

Are we seeing glimmers of hope with the next wave of I-O therapies? Check out our recent blog post, which features some reflections on data recently presented at ESMO, including from our Phase 1 study of HST-1011.

Today, we’re presenting preclinical data for our MALT1 CBM signalosome glue, highlighting the potential in NF-kB-driven solid tumors, at the 36th EORTC-NCI-AACR Symposium. If you’re on-site in Barcelona, be sure to swing by the poster! hotspotthera.com/press_release/…

This weekend, we will be presenting additional biomarker data from the Phase 1 study of HST-1011, our novel CBL-B inhibitor, at #SITC24. Check out our press release to learn more and stop by the poster Saturday if you’re in Houston! hotspotthera.com/press_release/…

The HotSpot team gathered for a potluck to enjoy foods ranging from smoked turkey to eggplant lasagna to sesame balls. What a treat to experience such a range of cooking and to come together ahead of the Thanksgiving Day holiday!

In our latest blog post, our CEO, Jonathan Montagu, explores the therapeutic promise of targeting transcription factors and highlights the growing wave of scientific innovations that are beginning to enable the drugging of this target class. Check it out: hotspotthera.com/a-new-wave-of-…

Today at #FOCIS2025, the HotSpot team will be presenting preclinical data from our small molecule IRF5 inhibitor program. Check out the presentation at 4:00 PM ET or stop by the poster if you’re in Boston today!

This afternoon, the HotSpot team presented encouraging preclinical data for our IRF5 program, supporting the potential of a potent and selective small molecule IRF5 inhibitor for a range of autoimmune diseases. Check out our press release to learn more! hotspotthera.com/press_release/…

The HotSpot team is thrilled to be on the ground at ESMO GI presenting preclinical data from our CBM signalosome inhibitor program. Check out our posters this Fri., Jul. 4, 15:30 CEST if you’re in Barcelona!

HotSpot team members are celebrating the holiday weekend presenting preclinical data from our CBM signalosome inhibitor program at ESMO GI, demonstrating its potential for the treatment of KRASG12X CRC. Check out our press release to learn more! hotspotthera.com/press_release/…

A “complex” solution to a “complex” problem? Check out our latest blog post that explores a potential approach to attacking KRAS G12X colorectal cancer via the CBM signalosome complex: lifescivc.com/2025/07/a-comp…

The HotSpot team took to the harbor for our annual summer outing to celebrate a year of hard work… And even got to spot our offices in the background! What a fun day on the water.

Thank you to our summer intern, Alina Pucci, for her help this summer! We wish her all the best as she heads back to college. And a special shout-out to Varuna for her mentorship!